HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis b virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma

Hyunsung Park, doyoung kim, Soo Jeong Kim, Haerim Chung, Hyunsoo Cho, Ji Eun Jang, June Won Cheong, Yoo Hong Min, Jae Woo Song, Jinseok Kim

Research output: Contribution to journalArticle

Abstract

Purpose Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)- negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.

Original languageEnglish
Pages (from-to)1121-1129
Number of pages9
JournalCancer Research and Treatment
Volume50
Issue number4
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Hepatitis Viruses
Stem Cell Transplantation
Hepatitis B Surface Antigens
Multiple Myeloma
Hepatitis B Antibodies
Hepatitis
Lymphoma
Hepatitis B virus
Serology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Hyunsung ; kim, doyoung ; Kim, Soo Jeong ; Chung, Haerim ; Cho, Hyunsoo ; Jang, Ji Eun ; Cheong, June Won ; Min, Yoo Hong ; Song, Jae Woo ; Kim, Jinseok. / HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis b virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 4. pp. 1121-1129.
@article{8ab97f8435e94188a061687c46b07d5d,
title = "HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis b virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma",
abstract = "Purpose Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)- negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1{\%} of patients (16.7{\%} with MM and 5.4{\%} with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.",
author = "Hyunsung Park and doyoung kim and Kim, {Soo Jeong} and Haerim Chung and Hyunsoo Cho and Jang, {Ji Eun} and Cheong, {June Won} and Min, {Yoo Hong} and Song, {Jae Woo} and Jinseok Kim",
year = "2018",
month = "10",
day = "1",
doi = "10.4143/crt.2017.329",
language = "English",
volume = "50",
pages = "1121--1129",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis b virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma. / Park, Hyunsung; kim, doyoung; Kim, Soo Jeong; Chung, Haerim; Cho, Hyunsoo; Jang, Ji Eun; Cheong, June Won; Min, Yoo Hong; Song, Jae Woo; Kim, Jinseok.

In: Cancer Research and Treatment, Vol. 50, No. 4, 01.10.2018, p. 1121-1129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis b virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma

AU - Park, Hyunsung

AU - kim, doyoung

AU - Kim, Soo Jeong

AU - Chung, Haerim

AU - Cho, Hyunsoo

AU - Jang, Ji Eun

AU - Cheong, June Won

AU - Min, Yoo Hong

AU - Song, Jae Woo

AU - Kim, Jinseok

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)- negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.

AB - Purpose Although hepatitis B surface antigen (HBsAg)-negative, hepatitis B core antibody (anti-HBc)- negative patients are not considered to be at risk for hepatitis B virus (HBV)-related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc-negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc-negative and 110 anti-HBc-positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc-negative MMs and one anti-HBc-positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg-negative and anti-HBc-positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc-negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=85054775781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054775781&partnerID=8YFLogxK

U2 - 10.4143/crt.2017.329

DO - 10.4143/crt.2017.329

M3 - Article

VL - 50

SP - 1121

EP - 1129

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -